All In Biotech

Drug Trial Radar · NCT02595944

Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 903 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

903

Planned (sponsor's estimate)

Start

Jul 22, 2016

Primary completion

May 31, 2027

Study completion May 31, 2027

Sponsor

Sponsor type
NIH
First posted
Nov 4, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase III ALCHEMIST treatment trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Conditions

  • Stage IB Lung Non-Small Cell Carcinoma AJCC v7
  • Stage II Lung Non-Small Cell Cancer AJCC v7
  • Stage IIIA Lung Non-Small Cell Cancer AJCC v7

Interventions

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Computed TomographyProcedure

    Undergo CT

  • Echocardiography TestProcedure

    Undergo ECHO

  • NivolumabBiological

    Given IV

  • Observation ActivityOther

    Undergo observation

  • Positron Emission TomographyProcedure

    Undergo PET-CT

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-free survival (DFS)Time frame: Time from randomization to the earliest event defined as disease recurrence, any new lung cancer (even in the opposite lung), or death from any cause at any known point in time, assessed up to 10 years
  2. Overall survival (OS)Time frame: From randomization to death from any cause, assessed up to 10 years

Locations

884 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • Southern Cancer Center PC-Daphne

    Daphne, Alabama

  • Southern Cancer Center PC-Mobile

    Mobile, Alabama

  • Southern Cancer Center PC-Providence

    Mobile, Alabama

  • Southern Cancer Center PC-Springhill

    Mobile, Alabama

  • Katmai Oncology Group

    Anchorage, Alaska

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • Mayo Clinic Hospital in Arizona

    Phoenix, Arizona

  • Mayo Clinic in Arizona

    Scottsdale, Arizona

  • Banner University Medical Center - Tucson

    Tucson, Arizona

  • University of Arizona Cancer Center-North Campus

    Tucson, Arizona

  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro

    Jonesboro, Arkansas

  • John L McClellan Memorial Veterans Hospital

    Little Rock, Arkansas

  • Kaiser Permanente-Anaheim

    Anaheim, California

  • PCR Oncology

    Arroyo Grande, California

  • Sutter Auburn Faith Hospital

    Auburn, California

  • Sutter Cancer Centers Radiation Oncology Services-Auburn

    Auburn, California

  • AIS Cancer Center at San Joaquin Community Hospital

    Bakersfield, California

  • Kaiser Permanente-Baldwin Park

    Baldwin Park, California

  • Kaiser Permanente-Bellflower

    Bellflower, California

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California

  • Mills-Peninsula Medical Center

    Burlingame, California

  • Sutter Cancer Centers Radiation Oncology Services-Cameron Park

    Cameron Park, California

  • Mercy San Juan Medical Center

    Carmichael, California

  • Eden Hospital Medical Center

    Castro Valley, California

  • University Oncology Associates

    Clovis, California

  • John Muir Medical Center-Concord

    Concord, California

  • City of Hope Corona

    Corona, California

  • Sutter Davis Hospital

    Davis, California

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Mercy Cancer Center - Elk Grove

    Elk Grove, California

  • Kaiser Permanente-Fontana

    Fontana, California

  • Palo Alto Medical Foundation-Fremont

    Fremont, California

  • Saint Jude Medical Center

    Fullerton, California

  • Kaiser Permanente South Bay

    Harbor City, California

  • Kaiser Permanente-Irvine

    Irvine, California

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • Loma Linda University Medical Center

    Loma Linda, California

  • Kaiser Permanente Los Angeles Medical Center

    Los Angeles, California

  • Los Angeles General Medical Center

    Los Angeles, California

Showing 40 of 884 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.